Yasunori Masuike
Papers
3
Total Citations
25
H-Index
2
About
Yasunori Masuike is a leading surgical oncologist whose work is reshaping the treatment landscape for advanced gastric and gastroesophageal junction cancers. His research centers on two critical frontiers: the clinical application of targeted therapies, particularly zolbetuximab for CLDN18.2-positive tumors, and the optimization of minimally invasive surgical techniques. Masuike’s most impactful contribution is his pioneering documentation of real-world adverse events from zolbetuximab-based chemotherapy, including the first reported cases of protein-losing enteropathy—a finding with 13 citations that directly informs patient safety in the GLOW and SPOTLIGHT trial era. He has also advanced the paradigm of conversion surgery, demonstrating that zolbetuximab-based regimens can render initially unresectable tumors operable, offering a potential cure where none existed before. Complementing this, his comparative analysis of robotic versus laparoscopic gastrectomy (10 citations) provides crucial three-year survival data, guiding surgical decision-making. Through these contributions, Masuike bridges targeted molecular therapy and surgical innovation, establishing new standards for managing advanced gastric cancer while meticulously documenting both the promise and the perils of emerging treatments.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3